Episode 79: ESMO 2023 - Gynaecological Oncology

As Oncology for the Inquisitive Mind's coverage of ESMO 2023 winds down, we bring some of the best presentations covering gynaecological cancer. An area of oncology that in many cases remains mired in the pre-immunotherapy and pre-targeted therapy ages, ESMO brought some much-needed positive trials in the areas of cervical cancer, as well as an interesting (albeit negative) study of the PARP-inhibitor olaparib that highlights some of the more practical challenges of running an international phase 3 study. As always, outcomes can always improve, but any progress in this very important area is always a welcome development.

Studies discussed in this episode (subscription may be required):

• A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial

• https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639091

• innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

• https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639430

• Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

• https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639154